Becton Dickinson & Co
Could not find a ticker for this position, may be a filing error
A global medical technology company, BD makes the everyday tools hospitals and labs rely on—syringes, IV catheters, infusion pumps, blood collection tubes, and surgical and diagnostic products sold under brands like BD Alaris and BD Pyxis. It was founded in 1897 when two salesmen, Maxwell Becton and Fairleigh Dickinson, met in a Texas train-station restaurant, discovered they shared the same birthday, and pooled their savings to start a medical supply business in New York City.
6.125% Mandatory Convertible Preferred Stock, Series A (depositary shares)
Granted 200.0K · Sold 13.9K
Granted 4.6K
Granted 4.6K · Sold 1.9K
Granted 15.3K · Sold 6.4K
Granted 1.7K
Granted 5.0K
Granted 36.0K
Granted 18.8K · Sold 7.0K
Granted 4.6K
Granted 31.9K · Sold 2.6K
Granted 3.5K · Sold 3.5K
Granted 21.8K
Granted 18.0K · Sold 935
Granted 38.5K · Sold 11.7K
Granted 3.8K
Granted 3.5K
Granted 9.9K
Granted 20.2K · Sold 6.4K
Granted 32.6K · Sold 13.8K
Sold 1.5K
Granted 4.6K
Granted 2.8K
Granted 820
Granted 35.0K · Sold 16.5K
Granted 4.6K · Bought 1.5K
Granted 9.2K · Sold 3.2K
Granted 2.7K
Granted 1.9K · Bought 5.3K
Granted 820
Granted 50.2K · Sold 17.7K
Granted 8.8K · Sold 4.4K
Granted 4.1K
Granted 4.8K
Granted 4.5K
Granted 2.1K
Granted 3.3K
Granted 2.2K
Granted 3.8K · Sold 1.5K
Granted 1.3K
Granted 1.3K
Granted 9.3K
Granted 14.3K
Granted 7.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Polen Thomas E JrChairman, CEO and President, Director · 23 transactions | +447.4% | 108.2K | 200.0K | — | 13.9K |
| Ring Timothy MDirector · 5 transactions | -22.1% | 61.4K | 4.6K | — | — |
| Scott Bertram LDirector · 8 transactions | +127.8% | 36.8K | 4.6K | — | 1.9K |
| Conroy AlexandreEVP of Integrated Supply Chain · 6 transactions | +67.1% | 36.8Kas of Feb 2022 | 15.3K | — | 6.4K |
| Larsen Marshall ODirector · 2 transactions | +25.8% | 28.9Kas of Jan 2023 | 1.7K | — | — |
| Reidy Christopher RCFO and EVP of Administration · 3 transactions | +3.3% | 28.6Kas of Nov 2021 | 5.0K | — | — |
| DelOrefice ChristopherEVP & Chief Financial Officer · 18 transactions | — | 27.2K | 36.0K | — | — |
| Lim James CExecutive Vice President · 5 transactions | +21.1% | 24.9Kas of Jun 2022 | 18.8K | — | 7.0K |
| Jones Christopher Ian MontagueDirector · 5 transactions | +206.6% | 24.3K | 4.6K | — | — |
| Neal Shana CarolEVP and Chief People Officer · 23 transactions | — | 24.0K | 31.9K | — | 2.6K |
| Fraser ClaireDirector · 8 transactions | +9.9% | 22.2K | 3.5K | — | 3.5K |
| Muhsin BilalEVP & President Connected Care · 2 transactions | — | 21.8K | 21.8K | — | — |
| Feld MichaelEVP, Chief Revenue Officer · 18 transactions | — | 19.7K | 18.0K | — | 935 |
| Goette RolandEVP and President, EMEA · 33 transactions | +87.7% | 17.7K | 38.5K | — | 11.7K |
| Mas Ribo AlbertoEVP and Pres, Life Sciences · 3 transactions | +24.7% | 15.3Kas of Nov 2021 | 3.8K | — | — |
| Burzik Catherine MDirector · 4 transactions | +22.3% | 14.3Kas of Jan 2025 | 3.5K | — | — |
| Ezell Antoine CEVP, President Americas & CMO · 14 transactions | +187.5% | 13.3Kas of Nov 2024 | 9.9K | — | — |
| Byrd RichardEVP & President Interventional · 20 transactions | — | 13.2K | 20.2K | — | 6.4K |
| Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm · 32 transactions | — | 13.2K | 32.6K | — | 13.8K |
| Rimel Rebecca WDirector · 4 transactions | -12% | 10.6Kas of Sep 2021 | — | — | 1.5K |
| Eckert R AndrewDirector · 5 transactions | +93.6% | 10.4K | 4.6K | — | — |
| Campion Simon DEVP and Segment President · 5 transactions | +22.4% | 10.3Kas of Feb 2022 | 2.8K | — | — |
| Pomeroy ClaireDirector · 1 transaction | +11.5% | 10.0Kas of Jan 2022 | 820 | — | — |
| Khichi Samrat S.EVP and General Counsel · 15 transactions | +126.7% | 9.3Kas of Dec 2022 | 35.0K | — | 16.5K |
| Henderson Jeffrey WilliamDirector · 6 transactions | +212.2% | 9.2K | 4.6K | 1.5K | — |
| Shan DavidEVP and Chief ISC Officer · 15 transactions | — | 8.9K | 9.2K | — | 3.2K |
| Roque VitorEVP & Chief Financial Officer · 2 transactions | — | 8.2K | 2.7K | — | — |
| Hayes GregoryDirector · 3 transactions | — | 7.2K | 1.9K | 5.3K | — |
| Melcher David FDirector · 1 transaction | +17.6% | 6.2Kas of Jan 2022 | 820 | — | — |
| Larson Betty DEVP HR & CHRO · 31 transactions | -10.8% | 5.9Kas of Feb 2022 | 50.2K | — | 17.7K |
| Hickey DavidEVP & President, Life Sciences · 10 transactions | +34.6% | 5.9Kas of Nov 2023 | 8.8K | — | 4.4K |
| Mocherla Pavan KumarEVP & President, Greater Asia · 9 transactions | — | 5.1K | 4.1K | — | — |
| Byington Carrie LDirector · 6 transactions | — | 5.0K | 4.8K | — | — |
| Brown William MDirector · 5 transactions | — | 4.7K | 4.5K | — | — |
| Quinn MichelleEVP and General Counsel · 4 transactions | — | 4.5Kas of Nov 2023 | 2.1K | — | — |
| Waldstreicher JoanneDirector · 4 transactions | — | 3.4K | 3.3K | — | — |
| Spikner Pamela L.SVP Controller & CAO · 3 transactions | — | 3.3K | 2.2K | — | — |
| Spoerel Thomas JSVPController & Chief Acct Off · 22 transactions | — | 2.2Kas of Jul 2024 | 3.8K | — | 1.5K |
| Huffines Robert LutherDirector · 2 transactions | — | 1.3K | 1.3K | — | — |
| Wright JacquelineDirector · 2 transactions | — | 1.3K | 1.3K | — | — |
| Grover RishiEVP and Chief ISC Officer · 1 transaction | — | 99as of Jul 2022 | 9.3K | — | — |
| Menziuso PeterEVP and President, BDI · 1 transaction | — | 0 | 14.3K | — | — |
| Minnix LaneshaEVP and General Counsel · 1 transaction | — | 0 | 7.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -106.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.